Abivax SA (ABVX)

Currency in EUR
115.50
0.00(0.00%)
Real-time Data·
ABVX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
101.60116.60
52 wk Range
6.55132.00
Key Statistics
Prev. Close
115.5
Open
103
Day's Range
101.6-116.6
52 wk Range
6.55-132
Volume
-
Average Volume (3m)
293.33K
1-Year Change
1,639.4578%
Book Value / Share
5.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABVX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
120.06
Upside
+3.95%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Abivax SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 120.06
(+3.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Kepler Cheuvreux
Buy180.00+55.84%130.00MaintainJun 30, 2026
Stifel
Buy115.00-0.43%-MaintainJun 30, 2026
Stifel
Buy100.00-13.42%68.00MaintainSep 09, 2025

Earnings

Latest Release
May 22, 2026
EPS / Forecast
-0.61 / -0.80
Revenue / Forecast
1.3M / 428.87K
EPS Revisions
Last 90 days

ABVX Income Statement

Compare ABVX to Peers and Sector

Metrics to compare
ABVX
Peers
Sector
Relationship
P/E Ratio
−20.0x−3.1x−0.4x
PEG Ratio
0.51−0.120.00
Price/Book
15.5x0.1x2.6x
Price / LTM Sales
1,349.3x20.9x3.0x
Upside (Analyst Target)
1.7%184.7%53.6%
Fair Value Upside
Unlock0.4%7.6%Unlock

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
13.98M17.55%1.16B
Other Institutional Investors
108.46M82.45%9.04B
Public Companies & Retail Investors
0.000.00%0.00
Total
122.45M100.00%10.2B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
UBS Asset Management AG9.76%7,774,999647,657
Darwin Global Management Limited9.70%7,728,672643,798

People Also Watch

122.50
SOIT
+4.43%
9.30
ALKAL
+6.16%
31.94
NANOB
-0.50%
34.10
AL2SI
+11.15%
170.86
SPCX
+4.06%

FAQ

What Is the Abivax SA (ABVX) Stock Price Today?

The Abivax SA stock price today is 115.50 EUR.

What Stock Exchange Does Abivax SA Trade On?

Abivax SA is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Abivax SA?

The stock symbol for Abivax SA is "ABVX."

What Is the Abivax SA Market Cap?

As of today, Abivax SA market cap is 9.20B EUR.

What Is Abivax SA's Earnings Per Share (TTM)?

The Abivax SA EPS (TTM) is -4.52.

When Is the Next Abivax SA Earnings Date?

Abivax SA will release its next earnings report on Sep 21, 2026.

From a Technical Analysis Perspective, Is ABVX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Abivax SA Stock Split?

Abivax SA has split 0 times.

How Many Employees Does Abivax SA Have?

Abivax SA has 80 employees.

What is the current trading status of Abivax SA (ABVX)?

As of Jul 01, 2026, Abivax SA (ABVX) is trading at a price of 115.50 EUR, with a previous close of 115.50 EUR. The stock has fluctuated within a day range of 101.60 EUR to 116.60 EUR, while its 52-week range spans from 6.55 EUR to 132.00 EUR.

What Is Abivax SA (ABVX) Price Target According to Analysts?

The average 12-month price target for Abivax SA is 120.06 EUR, with a high estimate of 180 EUR and a low estimate of 70 EUR. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +3.95% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.